These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 34878770)

  • 1. Discovery of AL-GDa62 as a Potential Synthetic Lethal Lead for the Treatment of Gastric Cancer.
    Luxenburger A; Bougen-Zhukov N; Fraser MG; Beetham H; Harris LD; Schmidt D; Cameron SA; Guilford PJ; Evans GB
    J Med Chem; 2021 Dec; 64(24):18114-18142. PubMed ID: 34878770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. E-cadherin-deficient cells have synthetic lethal vulnerabilities in plasma membrane organisation, dynamics and function.
    Godwin TD; Kelly ST; Brew TP; Bougen-Zhukov NM; Single AB; Chen A; Stylianou CE; Harris LD; Currie SK; Telford BJ; Beetham HG; Evans GB; Black MA; Guilford PJ
    Gastric Cancer; 2019 Mar; 22(2):273-286. PubMed ID: 30066183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A high-throughput screen to identify novel synthetic lethal compounds for the treatment of E-cadherin-deficient cells.
    Beetham H; Chen A; Telford BJ; Single A; Jarman KE; Lackovic K; Luxenburger A; Guilford P
    Sci Rep; 2019 Aug; 9(1):12511. PubMed ID: 31467357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic Lethal Screens Identify Vulnerabilities in GPCR Signaling and Cytoskeletal Organization in E-Cadherin-Deficient Cells.
    Telford BJ; Chen A; Beetham H; Frick J; Brew TP; Gould CM; Single A; Godwin T; Simpson KJ; Guilford P
    Mol Cancer Ther; 2015 May; 14(5):1213-23. PubMed ID: 25777964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptomic profiling and quantitative high-throughput (qHTS) drug screening of CDH1 deficient hereditary diffuse gastric cancer (HDGC) cells identify treatment leads for familial gastric cancer.
    Chen I; Mathews-Greiner L; Li D; Abisoye-Ogunniyan A; Ray S; Bian Y; Shukla V; Zhang X; Guha R; Thomas C; Gryder B; Zacharia A; Beane JD; Ravichandran S; Ferrer M; Rudloff U
    J Transl Med; 2017 May; 15(1):92. PubMed ID: 28460635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allosteric AKT Inhibitors Target Synthetic Lethal Vulnerabilities in E-Cadherin-Deficient Cells.
    Bougen-Zhukov N; Nouri Y; Godwin T; Taylor M; Hakkaart C; Single A; Brew T; Permina E; Chen A; Black MA; Guilford P
    Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31540244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. THE STUDY OF THE EXPRESSION OF CDH1, KI67, P53 AND HER2 IN DIFFUSE GASTRIC CARCINOMA.
    Muzashvili T; Tutisani A; Chabradze G; Beridze N; Museridze N
    Georgian Med News; 2020 Feb; (299):147-150. PubMed ID: 32242863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview on new progress of hereditary diffuse gastric cancer with
    Hu MN; Hu SH; Zhang XW; Xiong SM; Deng H
    Tumori; 2020 Oct; 106(5):346-355. PubMed ID: 32811340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical spectrum and pleiotropic nature of
    Figueiredo J; Melo S; Carneiro P; Moreira AM; Fernandes MS; Ribeiro AS; Guilford P; Paredes J; Seruca R
    J Med Genet; 2019 Apr; 56(4):199-208. PubMed ID: 30661051
    [No Abstract]   [Full Text] [Related]  

  • 10. Loss of E-Cadherin Leads to Druggable Vulnerabilities in Sphingolipid Metabolism and Vesicle Trafficking.
    Brew T; Bougen-Zhukov N; Mitchell W; Decourtye L; Schulpen E; Nouri Y; Godwin T; Guilford P
    Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new mutation of the CDH1 gene in a patient with an aggressive signet-ring cell carcinoma of the stomach.
    Caggiari L; Miolo G; Canzonieri V; De Zorzi M; Alessandrini L; Corona G; Cannizzaro R; Santeufemia DA; Cossu A; Buonadonna A; De Re V
    Cancer Biol Ther; 2018 Apr; 19(4):254-259. PubMed ID: 29131691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early genetic counseling and detection of CDH1 mutation in asymptomatic carriers improves survival in hereditary diffuse gastric cancer.
    Moslim MA; Heald B; Tu C; Burke CA; Walsh RM
    Surgery; 2018 Oct; 164(4):754-759. PubMed ID: 30145018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer.
    Kaurah P; MacMillan A; Boyd N; Senz J; De Luca A; Chun N; Suriano G; Zaor S; Van Manen L; Gilpin C; Nikkel S; Connolly-Wilson M; Weissman S; Rubinstein WS; Sebold C; Greenstein R; Stroop J; Yim D; Panzini B; McKinnon W; Greenblatt M; Wirtzfeld D; Fontaine D; Coit D; Yoon S; Chung D; Lauwers G; Pizzuti A; Vaccaro C; Redal MA; Oliveira C; Tischkowitz M; Olschwang S; Gallinger S; Lynch H; Green J; Ford J; Pharoah P; Fernandez B; Huntsman D
    JAMA; 2007 Jun; 297(21):2360-72. PubMed ID: 17545690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDH1 somatic alterations in Mexican patients with diffuse and mixed sporadic gastric cancer.
    Bustos-Carpinteyro AR; Oliveira C; Sousa A; Oliveira P; Pinheiro H; Carvalho J; Magaña-Torres MT; Flores-Miramontes MG; Aguilar-Lemarroy A; Jave-Suárez LF; Peregrina-Sandoval J; Cruz-Ramos JA; Sánchez-López JY
    BMC Cancer; 2019 Jan; 19(1):69. PubMed ID: 30642281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accuracy of Hereditary Diffuse Gastric Cancer Testing Criteria and Outcomes in Patients With a Germline Mutation in CDH1.
    van der Post RS; Vogelaar IP; Manders P; van der Kolk LE; Cats A; van Hest LP; Sijmons R; Aalfs CM; Ausems MG; Gómez García EB; Wagner A; Hes FJ; Arts N; Mensenkamp AR; van Krieken JH; Hoogerbrugge N; Ligtenberg MJ
    Gastroenterology; 2015 Oct; 149(4):897-906.e19. PubMed ID: 26072394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cleft lip/palate and hereditary diffuse gastric cancer: report of a family harboring a CDH1 c.687 + 1G > A germline mutation and review of the literature.
    Obermair F; Rammer M; Burghofer J; Malli T; Schossig A; Wimmer K; Kranewitter W; Mayrbaeurl B; Duba HC; Webersinke G
    Fam Cancer; 2019 Apr; 18(2):253-260. PubMed ID: 30306390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. E-Cadherin-Deficient Epithelial Cells Are Sensitive to HDAC Inhibitors.
    Decourtye-Espiard L; Bougen-Zhukov N; Godwin T; Brew T; Schulpen E; Black MA; Guilford P
    Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic total gastrectomy in hereditary diffuse gastric cancer: identification of two novel CDH1 gene mutations-a clinical observational study.
    Bardram L; Hansen TV; Gerdes AM; Timshel S; Friis-Hansen L; Federspiel B
    Fam Cancer; 2014 Jun; 13(2):231-42. PubMed ID: 24389957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline CDH1 mutations are a significant contributor to the high frequency of early-onset diffuse gastric cancer cases in New Zealand Māori.
    Hakkaart C; Ellison-Loschmann L; Day R; Sporle A; Koea J; Harawira P; Cheng S; Gray M; Whaanga T; Pearce N; Guilford P
    Fam Cancer; 2019 Jan; 18(1):83-90. PubMed ID: 29589180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and functional characterization of the CDH1 germline variant c.1679C>G in three unrelated families with hereditary diffuse gastric cancer.
    Pena-Couso L; Perea J; Melo S; Mercadillo F; Figueiredo J; Sanches JM; Sánchez-Ruiz A; Robles L; Seruca R; Urioste M
    Eur J Hum Genet; 2018 Sep; 26(9):1348-1353. PubMed ID: 29769627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.